NASDAQ:EVLO Evelo Biosciences (EVLO) Stock Price, News & Analysis → AI Cracks Open Largest Untapped Energy Reserve on Earth (From Banyan Hill Publishing) (Ad) Free EVLO Stock Alerts $0.06 0.00 (0.00%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$0.06▼$0.0750-Day Range$0.04▼$0.0752-Week Range$0.03▼$13.93Volume32,848 shsAverage Volume50,839 shsMarket Capitalization$1.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Evelo Biosciences alerts: Email Address Ad Porter & CompanyMy next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.Click here now to sign up About Evelo Biosciences Stock (NASDAQ:EVLO)Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Read More EVLO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVLO Stock News HeadlinesFebruary 22, 2024 | benzinga.comEvelo Biosciences Stock (OTC:EVLO), Short Interest ReportNovember 24, 2023 | msn.comEvelo Biosciences, a microbiome company launched by Flagship, shuts downMarch 18, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… November 22, 2023 | bizjournals.comFlagship-backed startup Evelo, behind failed eczema drug, to dissolveNovember 14, 2023 | finance.yahoo.comFMR LLC Reduces Stake in Evelo Biosciences IncNovember 10, 2023 | morningstar.comEvelo Biosciences Inc EVLONovember 2, 2023 | finance.yahoo.comQ3 2023 Horizon Technology Finance Corp Earnings CallNovember 2, 2023 | finance.yahoo.comHorizon Technology Finance Corporation (NASDAQ:HRZN) Q3 2023 Earnings Call TranscriptMarch 18, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.November 1, 2023 | msn.comEvelo Biosciences (EVLO) Price Target Increased by 53.85% to 10.20October 19, 2023 | msn.comTD Cowen Downgrades Evelo Biosciences (EVLO)October 18, 2023 | finance.yahoo.comEvelo (EVLO) Drops 59% on Flunking Psoriasis Drug StudyOctober 17, 2023 | marketwatch.comEvelo Biosciences Shares Down 58% After Unfavorable EDP2939 ResultsOctober 17, 2023 | markets.businessinsider.comHold Rating on Evelo Biosciences amid Unfavorable Outcomes and Strategic Changes: An Analyst Recommendation ReportOctober 17, 2023 | seekingalpha.comEvelo drops as mid-stage trial for psoriasis drug failsOctober 17, 2023 | proactiveinvestors.comEvelo Biosciences shares tank 46% after trial failureOctober 17, 2023 | markets.businessinsider.comEvelo Biosciences: EDP2939-101 Study Fails To Meet Endpoint; To Explore Strategic AlternativesOctober 17, 2023 | msn.comWhy Is Psoriasis Company Evelo Biosciences Stock Plunging Today?October 17, 2023 | marketwatch.comEvelo Biosciences Reviewing Alternatives After Study Didn't Meet EndpointOctober 17, 2023 | marketwatch.comEvelo Biosciences to review options after Phase 2 trial of psoriasis treatment fails to meet main goalOctober 17, 2023 | finance.yahoo.comEvelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate PsoriasisAugust 18, 2023 | seekingalpha.comEvelo Biosciences down 39% as 13M share offering beginsAugust 14, 2023 | finanznachrichten.deEvelo Biosciences, Inc.: Evelo Biosciences Announces Second Quarter Financial Results and Recent Business HighlightsAugust 14, 2023 | finance.yahoo.comEvelo Biosciences Announces Second Quarter Financial Results and Recent Business HighlightsAugust 11, 2023 | finance.yahoo.comFMR LLC Acquires Significant Stake in Evelo Biosciences IncJuly 27, 2023 | msn.comMorgan Stanley Maintains Evelo Biosciences (EVLO) Equal-Weight RecommendationJuly 21, 2023 | benzinga.comWhy Are velo Biosciences Stock Is Trading Higher Today?See More Headlines Receive EVLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/27/2021Today3/18/2024Next Earnings (Estimated)3/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:EVLO CUSIPN/A CIK1694665 Webwww.evelobio.com Phone(617) 577-0300FaxN/AEmployees66Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($13.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-114,530,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-189.58% Debt Debt-to-Equity RatioN/A Current Ratio0.48 Quick Ratio0.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.92) per share Price / Book-0.06Miscellaneous Outstanding Shares18,980,000Free Float18,789,000Market Cap$1.06 million OptionableNo Data Beta2.04 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Craig R. Jalbert CIRA (Age 62)President, Secretary, Principal Executive, Financial and Accounting Officer & Director Dr. Chun Zhang Ph.D.Chief Technical Operations & Quality OfficerDr. Mark Bodmer Ph.D. (Age 66)Chief Scientific Officer and President of Research & Development Comp: $668.8kMs. Jessica CotroneVP & Head of CommunicationsMs. Leslie Wardwell-Scott Ph.D.VP and Head of Corporate Development & Strategic IntegrationDr. Andrea Itano Ph.D.Head of ResearchDr. Duncan McHale M.D. (Age 57)MBBS, Ph.D., Chief Medical Officer Comp: $661.97kMr. Douglas MaslinSenior Director & Immunology Clinical LeadMore ExecutivesKey CompetitorsBaudax BioNASDAQ:BXRXCingulateNASDAQ:CINGTenax TherapeuticsNASDAQ:TENXNeptune Wellness SolutionsNASDAQ:NEPTNovaBay PharmaceuticalsNYSE:NBYView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 201,815 shares on 1/1/2024Ownership: 1.885%Mark BodmerSold 3,163 sharesTotal: $1,043.79 ($0.33/share)Marella ThorellSold 1,811 sharesTotal: $597.63 ($0.33/share)Simba GillSold 172 sharesTotal: $56.76 ($0.33/share)Simba GillSold 1,996 sharesTotal: $7,864.24 ($3.94/share)View All Insider TransactionsView All Institutional Transactions EVLO Stock Analysis - Frequently Asked Questions Should I buy or sell Evelo Biosciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EVLO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EVLO, but not buy additional shares or sell existing shares. View EVLO analyst ratings or view top-rated stocks. How have EVLO shares performed in 2024? Evelo Biosciences' stock was trading at $0.0615 at the beginning of 2024. Since then, EVLO shares have decreased by 8.9% and is now trading at $0.0560. View the best growth stocks for 2024 here. When is Evelo Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our EVLO earnings forecast. How were Evelo Biosciences' earnings last quarter? Evelo Biosciences, Inc. (NASDAQ:EVLO) issued its quarterly earnings data on Wednesday, October, 27th. The company reported ($12.60) earnings per share for the quarter, missing analysts' consensus estimates of ($10.80) by $1.80. During the same quarter last year, the business posted ($9.00) EPS. When did Evelo Biosciences' stock split? Shares of Evelo Biosciences reverse split before market open on Friday, June 30th 2023. The 1-20 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Evelo Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX). When did Evelo Biosciences IPO? (EVLO) raised $85 million in an IPO on Wednesday, May 9th 2018. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager. Who are Evelo Biosciences' major shareholders? Evelo Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Duncan Mchale, Marella Thorell, Mark Bodmer, Simba Gill, Stephen J Carriere and Ventures Fund Iv Gene Flagship. View institutional ownership trends. How do I buy shares of Evelo Biosciences? Shares of EVLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EVLO) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingStock-Picking AI Predicts #1 Stock of 2024AltimetrySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.